What is a Bone Marrow Transplant?
Bone marrow is the soft tissue inside our bones that produces blood cells:
- Red blood cells: Carry oxygen around the body.
- White blood cells: Fight infections.
- Platelets: Help prevent bleeding.
A bone marrow transplant uses blood-forming stem cells to restore the production of healthy blood cells.
Despite its name, stem cells are now commonly collected from the bloodstream rather than directly from the bone marrow.
The transplanted stem cells are given through a vein, much like a blood transfusion. It is not a surgical operation to replace the bone marrow.
Why is a Bone Marrow Transplant Needed?
Stem cell transplantation may be recommended for certain diseases, including:
- Acute leukaemia: Acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL).
- Lymphoma: Hodgkin lymphoma and certain non-Hodgkin lymphomas.
- Multiple myeloma.
- Myelodysplastic syndromes (MDS).
- Aplastic anaemia: Severe failure of the bone marrow to produce blood cells.
- Other selected disorders: Including certain inherited blood diseases and immune disorders.
Not every patient with these conditions needs a transplant. The decision depends on the disease, its response to treatment, the patient's fitness and the expected benefits and risks.
1. Types of Bone Marrow Transplantation
There are two main types.
Autologous Transplant (Auto-HSCT)
An autologous transplant uses the patient's own stem cells.
Stem cells are collected, usually frozen, and returned to the patient after high-dose chemotherapy.
This allows doctors to give intensive chemotherapy that would otherwise cause prolonged bone marrow failure.
Autologous transplantation is commonly used for:
- Multiple myeloma.
- Certain lymphomas.
- Selected other conditions.
Advantages:
- No donor is required.
- No HLA matching is needed.
- No conventional graft-versus-host disease (GVHD).
- Recovery is generally faster than with allogeneic transplantation.
Limitations:
- There is no donor-derived immune attack against cancer.
- The original disease may still relapse.
Allogeneic Transplant (Allo-HSCT)
An allogeneic transplant uses stem cells from another person.
The donor may be a family member or an unrelated volunteer.
The donor's stem cells establish a new blood-forming and immune system in the patient.
An important advantage is the graft-versus-leukaemia (GVL) effect, in which donor immune cells may recognise and destroy remaining cancer cells.
Allogeneic transplantation is commonly used for:
- Acute myeloid leukaemia.
- Acute lymphoblastic leukaemia.
- Myelodysplastic syndromes.
- Aplastic anaemia.
- Selected other blood and immune disorders.
Advantages:
- Provides a new blood-forming system.
- Can produce a beneficial immune attack against cancer.
- May offer a cure for certain diseases.
Limitations:
- Requires a suitable donor.
- Greater risk of immune complications.
- Graft-versus-host disease may occur.
- Recovery is usually longer and more complex.
Autologous vs Allogeneic Transplant
| Feature | Autologous | Allogeneic | |---|---|---| | Stem cell source | Patient | Donor | | Common uses | Myeloma, lymphoma | Leukaemia, MDS, aplastic anaemia | | HLA matching | Not required | Usually required | | GVHD risk | No conventional GVHD | Present | | Donor immune effect | Absent | Graft-versus-leukaemia effect | | Recovery | Usually faster | Often longer | | Main concerns | Infection, toxicity, relapse | Infection, GVHD, graft failure, relapse |
2. Types of Allogeneic Donors
Several types of donors may be considered.
Fully Matched Sibling Donor
A brother or sister who has matching HLA tissue markers.
Each full sibling has approximately a 25% chance of being HLA-identical.
A fully matched sibling may be an excellent donor, although donor age, health and other factors also influence the choice.
Haploidentical Donor (Half-Matched)
A haploidentical donor shares one of the patient's two inherited HLA sets.
Common donors include:
- Parents.
- Children.
- Brothers or sisters.
Parents and biological children are usually haploidentical matches.
Modern transplant techniques, particularly the use of post-transplant cyclophosphamide, have made haploidentical transplantation an important option when a fully matched donor is unavailable.
Matched Unrelated Donor (MUD)
A matched unrelated donor is a volunteer identified through a national or international stem cell donor registry.
Although unrelated to the patient, the donor may have closely matching HLA markers.
Unrelated donor transplantation is widely used when a suitable family donor is unavailable.
Umbilical Cord Blood Transplant
Stem cells are obtained from donated umbilical cord blood collected after childbirth.
Cord blood has certain advantages, including less stringent HLA matching requirements.
However, the number of stem cells in a single cord blood unit may be insufficient for an adult patient.
This can result in:
- Slower engraftment.
- Longer periods of low blood counts.
- Increased risk of infection.
- Higher risk of graft failure.
Cord blood transplantation is now less commonly used in adults, particularly because haploidentical transplantation provides another donor option.
Nevertheless, cord blood remains useful in selected circumstances.
Which Donor is Best?
The best donor is not necessarily a sibling.
The transplant team considers:
- Degree of HLA matching.
- Donor age and health.
- Donor availability.
- Stem cell source.
- Patient's underlying disease.
- Risk of GVHD and other complications.
3. What is HLA Typing?
HLA stands for Human Leukocyte Antigen.
HLA markers are proteins found on the surface of most cells. They help the immune system distinguish the body's own cells from foreign cells.
Before an allogeneic transplant, blood samples are taken from the patient and potential donors for HLA typing.
Important HLA markers include:
- HLA-A
- HLA-B
- HLA-C
- HLA-DRB1
- HLA-DQB1
A fully matched donor is commonly described as a 10/10 match, meaning the donor and recipient match at both copies of these five HLA genes.
Some transplant programmes use an 8/8 matching system based on four of these genes.
A haploidentical donor shares one inherited HLA haplotype with the patient.
Good HLA matching helps reduce the risks of graft rejection and GVHD.
However, modern transplant techniques allow successful transplantation even with partially matched donors.
4. How is a Bone Marrow Transplant Performed?
The transplant process involves several stages.
Step 1: Pre-Transplant Assessment
Before transplantation, the patient undergoes a detailed medical assessment.
This may include:
- Blood tests.
- Heart and lung function tests.
- Kidney and liver function tests.
- Screening for infections.
- Assessment of the underlying disease.
- HLA typing and donor selection for allogeneic transplantation.
The aim is to determine whether the patient is fit enough to undergo transplantation and to identify potential risks.
Step 2: Stem Cell Collection
Stem cells are usually collected from the bloodstream using a procedure called apheresis.
Before collection, the donor or patient may receive injections of granulocyte colony-stimulating factor (G-CSF).
G-CSF encourages stem cells to move from the bone marrow into the bloodstream.
During apheresis, blood passes through a machine that separates and collects stem cells. The remaining blood is returned to the person.
Alternatively, stem cells may be collected directly from the pelvic bones under anaesthesia.
Step 3: Conditioning Treatment
Conditioning refers to chemotherapy, sometimes combined with total body irradiation, given before stem cell infusion.
Its purposes include:
- Destroying remaining cancer cells.
- Suppressing the immune system to allow donor stem cells to grow.
- Creating conditions that support new blood formation.
There are two main approaches.
Myeloablative Conditioning (MAC)
This uses intensive chemotherapy, sometimes with radiotherapy, to profoundly suppress or destroy the patient's bone marrow.
It is generally used in patients who can tolerate intensive treatment.
Reduced-Intensity Conditioning (RIC)
This uses less intensive treatment.
It is often considered for older patients or those with medical conditions that make full-intensity conditioning unsuitable.
In allogeneic transplantation, RIC relies more heavily on the donor immune system to control the disease.
Reduced-intensity transplantation is not risk-free. Serious infections, GVHD and other complications may still occur.
Step 4: Stem Cell Infusion (Day 0)
The day of stem cell infusion is called Day 0.
The stem cells are infused through a central venous catheter, much like a blood transfusion.
The procedure itself is usually painless and does not require surgery.
The infused stem cells travel through the bloodstream and eventually settle in the bone marrow.
Step 5: Supportive Care
Following conditioning, blood counts become very low.
Patients are particularly vulnerable to infections and bleeding.
Supportive care may include:
- Red blood cell transfusions.
- Platelet transfusions.
- Antibiotics, antifungal and antiviral medicines.
- G-CSF injections in selected patients.
- Intravenous fluids.
- Nutritional support.
- Treatment of nausea, vomiting and mouth ulcers.
- Medicines to prevent GVHD after allogeneic transplantation.
Patients require close monitoring and may need protective infection-control precautions during severe neutropenia.
Step 6: Engraftment and Recovery
The transplanted stem cells gradually begin producing new blood cells.
This process is called engraftment.
Once blood counts recover and the patient is medically stable, discharge from hospital may be possible.
However, recovery continues for months after transplantation.
5. What is Engraftment?
Engraftment occurs when transplanted stem cells establish themselves in the bone marrow and begin producing blood cells.
Neutrophil engraftment is commonly defined as an absolute neutrophil count of at least 0.5 × 10⁹/L for three consecutive days.
Typical Time to Neutrophil Engraftment
- Autologous peripheral blood stem cells: 10–14 days
- Allogeneic peripheral blood stem cells: 14–21 days
- Allogeneic bone marrow: 2–4 weeks
- Cord blood: Often 3–5 weeks or longer
These are approximate ranges. Actual recovery depends on the stem cell source, cell dose, conditioning regimen and other factors.
Chimerism Testing
After allogeneic transplantation, doctors may perform chimerism testing.
This measures the proportion of blood-forming cells that originate from the donor.
Chimerism results help doctors monitor donor cell establishment and identify potential graft problems.
Engraftment does not mean that the immune system has fully recovered.
Immune recovery may take many months and sometimes one to two years or longer after allogeneic transplantation.
6. Possible Complications
Bone marrow transplantation is an intensive treatment with potentially serious complications.
Early Complications
Infections
Bacterial, fungal and viral infections can occur when white blood cell counts are low or the immune system is suppressed.
Some infections may be life-threatening.
Bleeding
Low platelet counts increase the risk of bruising and bleeding.
Mucositis
Chemotherapy may cause painful inflammation and ulcers in the mouth and digestive tract.
Nausea, Vomiting and Diarrhoea
These are common side effects of conditioning treatment.
Organ Toxicity
Chemotherapy and other transplant treatments may affect the liver, kidneys, lungs or heart.
Graft Failure
In some patients, the transplanted stem cells fail to establish adequate blood production.
Acute Graft-versus-Host Disease
This is a complication of allogeneic transplantation.
Late Complications
Possible long-term complications include:
- Chronic GVHD.
- Persistent or recurrent infections.
- Delayed immune recovery.
- Infertility or early menopause.
- Hormonal problems.
- Cataracts.
- Heart, lung, liver or kidney problems.
- Secondary cancers.
- Relapse of the original disease.
Not every patient develops these complications.
The risks depend on the type of transplant, underlying disease, age, general health and treatment used.
7. Graft-versus-Host Disease (GVHD)
GVHD is one of the most important complications of allogeneic transplantation.
It occurs when immune cells from the donor recognise the patient's tissues as foreign and attack them.
There are two main forms.
Acute GVHD
Acute GVHD commonly develops during the first 100 days after transplantation, although it can occur later.
It mainly affects three organ systems.
Skin
- Red rash.
- Itching.
- Widespread skin inflammation.
- Blistering or peeling in severe cases.
Intestines
- Watery diarrhoea.
- Abdominal pain.
- Nausea or vomiting.
- Gastrointestinal bleeding in severe cases.
Liver
- Abnormal liver function tests.
- Increased bilirubin.
- Jaundice in some patients.
Acute GVHD is graded according to the organs involved and the severity of symptoms.
Chronic GVHD
Chronic GVHD usually develops months after transplantation and can affect several organs.
Possible symptoms include:
- Dry eyes.
- Dry mouth.
- Mouth ulcers or sensitivity.
- Skin thickening or tightening.
- Changes in skin pigmentation.
- Joint stiffness.
- Reduced range of movement.
- Breathing difficulties due to lung involvement.
- Liver abnormalities.
- Genital dryness, irritation or scarring.
Chronic GVHD can persist for years and may significantly affect quality of life.
Prevention of GVHD
Medicines are routinely given after allogeneic transplantation to reduce the risk of GVHD.
These may include:
- Tacrolimus.
- Ciclosporin.
- Methotrexate.
- Mycophenolate mofetil.
- Post-transplant cyclophosphamide (PTCy).
The choice depends on the donor type and transplant protocol.
Post-transplant cyclophosphamide is particularly important in haploidentical transplantation and is increasingly used with other donor types.
Treatment of GVHD
Treatment depends on the severity and organs affected.
Corticosteroids are commonly used for significant acute GVHD.
Other immunosuppressive medicines may be required.
For patients whose GVHD does not respond adequately to steroids, treatments such as ruxolitinib may be considered.
The aim is to control GVHD while preserving as much of the beneficial graft-versus-leukaemia effect as possible.
8. Recovery After Transplantation
Recovery continues long after the patient leaves hospital.
Patients usually require frequent follow-up appointments, particularly during the first few months.
Follow-up includes:
- Blood count monitoring.
- Kidney and liver function tests.
- Infection surveillance.
- Monitoring for GVHD.
- Chimerism testing when indicated.
- Assessment for relapse of the original disease.
- Adjustment of immunosuppressive medicines.
Precautions After Discharge
Patients should:
- Avoid close contact with people who have infectious illnesses.
- Practise good hand hygiene.
- Follow food safety recommendations.
- Take prescribed medicines consistently.
- Attend scheduled follow-up appointments.
- Report new symptoms promptly.
- Avoid live vaccines until specifically cleared by the transplant team.
Vaccinations often need to be repeated because immunity from previous vaccinations may be lost after transplantation.
The transplant team will provide an appropriate vaccination schedule.
Many patients gradually resume normal activities, although fatigue may persist for several months.
Recovery after allogeneic transplantation is generally longer and more complex than after autologous transplantation.
9. What Determines Transplant Success?
Transplant outcomes depend on several factors:
- Type and stage of the underlying disease.
- Whether the disease is in remission before transplantation.
- Patient's age and general fitness.
- Other medical conditions.
- Donor compatibility.
- Stem cell source.
- Conditioning regimen.
- Development of infections or GVHD.
- Risk of disease relapse.
Transplantation may offer a cure for certain blood cancers and bone marrow disorders.
However, successful engraftment does not guarantee a cure.
The transplant team will discuss the expected benefits, relapse risk and treatment-related mortality for each individual patient.
Next Steps
If bone marrow transplantation has been recommended:
- Understand the indication. Discuss why transplantation is needed and whether an autologous or allogeneic transplant is appropriate.
- Identify a suitable donor. For allogeneic transplantation, arrange HLA typing for appropriate family members and consider other donor options.
- Complete the pre-transplant assessment. This includes evaluation of organ function, infection screening and disease status.
- Discuss fertility preservation. Conditioning treatment may affect future fertility.
- Plan for hospitalisation and recovery. Consider caregiver support, costs, time away from work and follow-up arrangements.
- Understand the risks. Discuss infection, GVHD, graft failure, relapse and other possible complications.
Urgent Warning Signs
Seek immediate medical attention if any of the following occurs during or after transplantation:
- Fever of 38°C or higher, chills or shaking.
- Shortness of breath, chest pain or difficulty breathing.
- Uncontrolled bleeding, black stools or blood in the urine.
- Severe or persistent diarrhoea, vomiting or abdominal pain.
- A rapidly spreading skin rash, blistering or peeling.
- Yellowing of the eyes or skin.
- Confusion, seizures or a sudden severe headache.
- Inability to drink fluids, markedly reduced urine output or severe weakness.
Do not wait for the next clinic appointment if these symptoms occur.
Contact the transplant team immediately or attend the nearest emergency department.
Fever after transplantation can indicate a serious infection even when the patient otherwise feels reasonably well.
References and Further Reading
- National Cancer Institute: Stem Cell Transplants in Cancer Treatment
- European Society for Blood and Marrow Transplantation (EBMT): The EBMT Handbook
- National Marrow Donor Program (NMDP)
This article provides general patient education. Transplant decisions and care plans must be individualised by the treating haematologist and transplant team.